Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.

Original languageEnglish
Pages (from-to)389-394
Number of pages6
JournalJapanese Journal of Antibiotics
Volume64
Issue number6
Publication statusPublished - Dec 2011

Fingerprint

Vancomycin
Methicillin-Resistant Staphylococcus aureus
Endocarditis
Aminoglycosides
Therapeutic Uses
Gentamicins
Therapeutics
Anti-Bacterial Agents
habekacin

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Microbiology (medical)

Cite this

@article{d6030c624eee4e64a9f6dd6c4b9562bc,
title = "Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA",
abstract = "Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.",
author = "Kentaro To and Noriko Miyake and Yoji Nagasaki and Nobuyuki Shimono",
year = "2011",
month = "12",
language = "English",
volume = "64",
pages = "389--394",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "6",

}

TY - JOUR

T1 - Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA

AU - To, Kentaro

AU - Miyake, Noriko

AU - Nagasaki, Yoji

AU - Shimono, Nobuyuki

PY - 2011/12

Y1 - 2011/12

N2 - Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.

AB - Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.

UR - http://www.scopus.com/inward/record.url?scp=84856173794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856173794&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 389

EP - 394

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 6

ER -